Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland.
Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland.
Testing for Mepolizumab Biosimilar Begins
Bio-Thera Solutions began a phase 1 study for a biosimilar candidate referencing Nucala (mepolizumab). The study would assess the pharmacokinetics and safety of the biosimilar (BAT2606) in healthy participants.
The randomized, double-blind, parallel group, single-dose study will include 207 healthy volunteers. Mepolizumab is an interleukin 5 antagonist monoclonal antibody that can be administered subcutaneously with a syringe or autoinjector device. Nucala is used to treat:
After the study is completed, Bio-Thera will conduct a global phase 3 study. The company said that it plans to apply for regulatory approval in the United States, China, the European Union, and other markets around the world.
Biocon Biologics Licenses Out to Yoshindo
Biocon Biologics entered into a licensing agreement with Yoshindo for the Japanese commercialization of 2 biosimilar candidates: an ustekinumab biosimilar and a denosumab biosimilar.
Under the deal’s terms, Yoshindo would have exclusive commercialization rights for the biosimilars in Japan in exchange for $700 million. Biocon Biologics would receive an upfront license fee along with additional payments dependent on the achievement of development milestones over the next few years. The companies did not disclose the exact financial terms of the deal.
The ustekinumab biosimilar references Stelara and will be used to treat autoimmune conditions including, psoriasis, Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The denosumab candidate references Prolia and is used to treat patients with osteoporosis and patients undergoing cancer treatments who are at a high risk of fracture. Phase 1 and phase 3 clinical trials for the biosimilars began in 2022.
“Once approved, these products will expand our offering of affordable, high quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas,” said Shreehas Tambe, deputy CEO of Biocon Biologics, in a statement.
Hukyndra Launches in Switzerland
Alvotech and STADA Arzneimittel announced that they launched Hukyndra, an adalimumab biosimilar referencing Humira, in Switzerland. Hukyndra launched as a high-concentration, low-volume, citrate-free formulation.
“Significant unmet needs for access to biologics exist for patients across Europe…. Our partnership with Alvotech enables STADA to deliver a broad range of high-quality biosimilars to European patients. Launches of Hukyndra in multiple markets is evidence of our commitment to broader access to critical therapies,” said Bryan Kim, head of global specialty and executive vice president of STADA.
STADA and Alvotech entered into their partnership in November 2019. The agreement includes 7 biosimilars, including Hukyndra. Alvotech is responsible for development and manufacturing and STADA is in charge of commercialization. In Switzerland, Hukyndra is being marketed by Spirig HealthCare, a subsidiary of STADA. The biosimilar will be made available in 80 mg/0.8mL and 40 mg/0.4 mL syringes for self-administration and 40 mg/0.4 mL prefilled autoinjector pens.
The European Medicines Agency granted Hukyndra marketing authorization in November 2021. In addition to Switzerland, Hukyndra is available in Austria, Estonia, France, Finland, Germany, Lithuania, Slovakia, and Sweden. The biosimilar has also been approved in the United Kingdom and is under review in the United States.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.